Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-20...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg, Otto Hemminki
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/087cc32668694de4896935b1599092b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:087cc32668694de4896935b1599092b9
record_format	dspace
spelling	oai:doaj.org-article:087cc32668694de4896935b1599092b92021-12-02T20:10:16ZProgress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.1932-620310.1371/journal.pone.0253236https://doaj.org/article/087cc32668694de4896935b1599092b92021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0253236https://doaj.org/toc/1932-6203Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.Kari HemminkiAsta FörstiAkseli HemminkiBörje LjungbergOtto HemminkiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0253236 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kari Hemminki Asta Försti Akseli Hemminki Börje Ljungberg Otto Hemminki Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
description	Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. In addition to the standard 1- and 5-year relative survival rates, we calculated the difference between these as a measure of how well survival was maintained between years 1 and 5. Relative 1- year survival rates increased almost linearly in both countries and reached 90% in Sweden and 80% in Finland. Although 5-year survival also developed favorably the difference between 1- and 5-year survival rates did not improve in Sweden suggesting that the gains in 5-year survival were entirely due to gains in 1-year survival. In Finland there was a gain in survival between years 1 and 5, but the gain in 1-years survival was the main contributor to the favorable 5-year survival. Age group specific analysis showed large survival differences, particularly among women. Towards the end of the follow-up period the differences narrowed but the disadvantage of the old patients remained in 5-year survival. The limitations of the study were lack of information on performed treatment and clinical stage in the NORDCAN database. In conclusion, the available data suggest that earlier diagnosis and surgical treatment of RCC have been the main driver of the favorable change in survival during the past 50 years. The main challenges are to reduce the age-specific survival gaps, particularly among women, and push survival gains past year 1.
format	article
author	Kari Hemminki Asta Försti Akseli Hemminki Börje Ljungberg Otto Hemminki
author_facet	Kari Hemminki Asta Försti Akseli Hemminki Börje Ljungberg Otto Hemminki
author_sort	Kari Hemminki
title	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_short	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_full	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_fullStr	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_full_unstemmed	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
title_sort	progress in survival in renal cell carcinoma through 50 years evaluated in finland and sweden.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/087cc32668694de4896935b1599092b9
work_keys_str_mv	AT karihemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden AT astaforsti progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden AT akselihemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden AT borjeljungberg progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden AT ottohemminki progressinsurvivalinrenalcellcarcinomathrough50yearsevaluatedinfinlandandsweden
_version_	1718374982845726720

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Ejemplares similares